FAQ: Soligenix CEO Presentation at H.C. Wainwright Global Investment Conference
Summary
Soligenix Inc. announced that CEO Christopher J. Schaber, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference in September 2025, with the on-demand presentation available starting September 5th and management participating in one-on-one meetings during the event.
What is the main announcement in this content?
Soligenix Inc. announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025.
When will the presentation be available and how can it be accessed?
The on-demand presentation will be available beginning September 5, 2025, at 7 a.m. ET through the conference platform.
Who is Christopher J. Schaber and what is his role at Soligenix?
Christopher J. Schaber, Ph.D., is the President and CEO of Soligenix Inc., a late-stage biopharmaceutical company focused on developing treatments for rare diseases.
What type of company is Soligenix and what does it focus on?
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, with two main business segments: Specialized BioTherapeutics and Public Health Solutions.
What are the key products in Soligenix’s Specialized BioTherapeutics segment?
The Specialized BioTherapeutics segment includes HyBryte™ (SGX301) for cutaneous T-cell lymphoma, SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases including oral mucositis, and SGX945 for Behcet’s Disease.
What vaccine programs does Soligenix’s Public Health Solutions segment include?
The Public Health Solutions segment includes RiVax® (ricin toxin vaccine), filovirus vaccines (Marburg and Ebola), and CiVax™ (COVID-19 vaccine candidate), all incorporating the proprietary ThermoVax® heat stabilization technology.
How is Soligenix’s Public Health Solutions business segment funded?
This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
Where can investors find the latest news and updates about Soligenix?
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX.
What additional opportunities will be available during the conference besides the presentation?
Soligenix management will also be participating in one-on-one meetings during the H.C. Wainwright Global Investment Conference event.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 192200